Coronavirus Madness = Booming Biotechs

Dear Penny Stock Millionaire,

People love to start a new year with big goals and aspirations … yet so many fail to follow through. I want to help you follow those dreams of becoming fina‌ncially fr‌ee. (Just don’t think it’s gonna be easy. It’s not. You’re gonna have to study your butt off.)

The stock market can offer unlimited possibilities for the most dedicated. But too many people don’t even understand market basics. That’s why I teach all my strategies to my students and pride myself on being one of the few truly transparent traders.

Use this as a guide to help you build your knowledge database. I can’t give you all the answers, but my goal is to help you focus on the most important things happening in the market right now.

Today, I’ll focus on one of the hottest sectors in the market right now — low-priced hot biotechs.

Why Are Biotechs Running?

2019 was a challenging year for the biotech sector. The stocks were especially beaten down in December as investors and funds sold their shares for tax losses.

The tax-loss selling in December is the critical first stage of the January effect. A lot of people sell their shares. So a lot of low-priced stocks get beaten down further than they should.

This isn’t rocket science … but I’m not saying you should buy every stock you can in December. Let the companies take a beating. Wait for the new year before you get too trigger happy.

2019 was a lousy year for biotechs… The prices were pushed down hard (I’ll show examples in a bit)… 2020 might just be the right setting for an explosive biotech run.

Anytime these crappy, beaten down companies have a glimmer of hope, they tend to spike further than most traders expect. Once a couple of these biotechs start running, it can become a self-fulfilling prophecy. Traders remember what type of stocks run and prepare for sympathy plays.

Since the start of the decade, almost every top percent gainer has been a biotech company. I’d guess that 60%–70% or even 80% of the largest low-priced multi-day winners the first few weeks of 2020 are biotech stocks.

Hot Biotech Examples

Most of these biotech companies have terrible — and I mean TERRIBLE — long-term charts. They’re beaten down, and many have had previous offerings just to keep the lights on.

Trillium Therapeutics Inc. (NASDAQ: TRIL)

TRIL has one of the best daily charts I’ve seen in a long time. But, zoom out to a three-year chart and you see how this company has been terrible for years.

When I see a daily chart that’s down for years, I’m always extra careful. I rarely hold these overnight. I’m always prepared to cut losses quickly. At the end of the day, these companies suck. There’s a reason they’re beaten down.

TRIL was different than most January effect plays … It started its run in December around 30 cents and spiked to a high of $3.90 on January 10. That’s a move of over 1,000% in less than a month.

There were multiple opportunities to play TRIL, and many of my top students played its multi-day breakout of over $1.75 earlier this month. There’s no one way to trade these stocks. I just want you to be aware of hot biotechs and the patterns my students use on them.

I capitalized on this volatile spiker a few times. Though usually, I avoid buying strength on these plays to minimize my risk. So, I dip bought TRIL on December 27 and January 3 using my classic morning panic dip buy pattern.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE)

SRNE also began its move at the end of 2019. The day after Christmas, SRNE started its run from the $1.50s to the $5s.

Chart1

SRNE chart: 2-month, 1-day candle — courtesy of StocksToTrade.com.

This biotech has been running for nearly a month. It’s crazy how predictable these patterns can become once you dedicate yourself to learning market history…

Every year, the same thing happens. Sometimes it’s in a different industry, but the theme is the same. January can bring new life to penny stocks.

La Jolla Pharmaceutical Company (NASDAQ: LJPC)

LPJC is a classic beaten-down chart. The company’s had a few difficult years. It ended up in the low $2s at the end of 2019…

Chart2

LJPC chart: 2-month, 1-day candle — courtesy of StocksToTrade.com

Again, since a lot of investors sold at the end of 2019, these failing biotechs can spike — they have fewer sellers. It’s basic supply and demand … The supply on these got whipped out. That allows them to spike much higher than normal.

LJPC is a great example of supply-and-demand imbalance. There were hardly any sellers after the start of 2020. So when the company had good news, it spiked from the $4s to about $9 in four days.

Applied Genetic Technologies Corporation (NASDAQ: AGTC)

AGTC was one of the biggest biotech runners this year — spiking from the low $3s to a high of $9.50 on January 9, 2020.

Chart3

AGTC chart: 2-month, 1-day candle — courtesy of StocksToTrade.com

The stock is holding up well. If it continues to hold, it may have a multi-day breakout similar to TRIL. But nothing’s guaranteed. It could fail, the company could have an offering, or it might do nothing.

I honestly don’t know. I don’t try to predict where these stocks will go. Instead, I react to the price action.

IVERIC bio, Inc. (NASDAQ: ISEE)

ISEE was one of the first biotechs to run and start the hot biotech stock trend. The company had good news in October and really started spiking at the end of 2019.

Chart4

ISEE chart: 2-month, 1-day candle — courtesy of StocksToTrade.com

Again, it’s not just about January — it’s about this time of year. A lot of money exchanges hands, and there’s usually more volume in the markets as investors readjust their positions for taxes.

I won’t lie to you — trading isn’t easy. My best students learn to think outside the box. They dedicate themselves to this profession. Don’t be too narrowly focused on one stock or one-time frame. Take a step back and look at the big picture.

Will Hot Biotechs Continue in 2020?

If you watch the news, you know about the outbreak of the Wuhan coronavirus in China. To make matters worse, the virus made it to the U.S., which has a lot of people on high alert. Last time there was an outbreak of this scale, a few biotechs and related stocks exploded.

So I’m watching the news closely to see if it sparks sector momentum. Especially for antiviral drug companies. If the outbreak spreads it could be a catalyst, but nothing’s guaranteed.

So will biotechs continue to be hot in 2020? I don’t know. It’s not like these biotechs have changed and are suddenly better companies.

You might hope that with all the money invested in this sector, some of these stocks will start running as they find drugs that work. But it’s a very inexact science.

No matter how you look at them … they’re crappy companies. But that’s why they can make 100%+ moves in a day. You won’t see well-established blue-chips move even 50% in a day.

Conclusion

Any biotech that has even a little bit of good news can spike. If it holds its initial spike, it can spike more into the close on days one, two, three … even days four and five. The longer it holds, the higher the odds of a short squeeze.

2020 has only just begun. There have been too many plays for me to capture. But I like to think of myself as a retired trader who only comes out of retirement when a play is SO GOOD I’m forced to take it.

So far in 2020, I’ve hardly had a break! Get on board, do your research, and ride the volatility momentum to take advantage of these stocks!

Regards,

Tim Sykes
Editor, Penny Stock Millionaires

You May Also Be Interested In:

Terms Every Trader NEEDS to Know

As we move closer to the new year, many people resolve to make better choices financially, and to do that you need to educate yourself. So in an effort to help you start your new year right, I’ve compiled need to know information for traders as we enter the end of 2019.

Timothy Sykes

Tim Sykes is the editor of Tim Sykes’ Weekly Fortunes, a bi-weekly penny stock trader.

He also writes the free daily e-letter, Tim Sykes’ Penny Stock Millionaires

Tim’s most famous for turning the $12,415 dollars he received at his Bar Mitzvah into more than $1.65 million dollars in trading profits by college graduation.

In 2003,...

View More By Timothy Sykes